A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab-Reference-Cited by-同舟云学术

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab

Published:2022-09 Issue:9 Volume:22 Page:1278
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Hentzien Maxime,Autran Brigitte,Piroth Lionel,Yazdanpanah Yazdan,Calmy Alexandra

Funder

AbbVie

ViiV Healthcare

Merck

Gilead Sciences

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference3 articles.

1. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies;Yamasoba;Lancet Infect Dis,2022

2. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection;Cao;Nature,2022

3. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19;Dougan;MedRxiv,2022

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutralizing antibodies to block viral entry and for identification of entry inhibitors;Antiviral Research;2024-04

2. A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants;Antibody Therapeutics;2024-03-28

3. Dynamic Profiling and Prediction of Antibody Response to SARS-CoV-2 Booster-Inactivated Vaccines by Microsample-Driven Biosensor and Machine Learning;Vaccines;2024-03-25

4. A tetravalent bispecific antibody outperforms the combination of its parental antibodies and neutralizes diverse SARS-CoV-2 variants;Clinical Immunology;2024-03

5. Dynamic Profiling and Prediction of Antibody Response to Booster Inactivated Vaccines by Microsample-driven Biosensor and Machine Learning;2024-01-26